ICYMI: Gene therapy provides hope for Huntington’s Disease patients
Latest News
- May 24
What They’re Saying: Strong Support for the MVP Act
- Apr 25
IGT Congressional Letter and Statement on the Re-Introduction of the MVP Act (H.R. 2666)
- Apr 11
Perspective: Advancing Hope for Andrew and Countless Others
- Mar 31
Our Healthcare Policies Must Account for the True Value of Transformative Gene Therapies
- Feb 23
Congressional Briefing: Realizing the Promise of Gene Therapy through Science & Policy
- Nov 2, 2022
ICYMI: Cure Sickle Cell Disease by 2030?
- Oct 13, 2022
A Bold Goal to Cure Sickle Cell Disease by 2030
- Jul 7, 2022
IGT Comments on CMS Fiscal Year 2023 Medicare Inpatient Prospective Payment Systems Proposed Rule
- Jun 17, 2022
New Resource: Understanding the Complexity of Gene Therapy Science & Manufacturing
- May 3, 2022
IGT Chairman Erik Paulsen Joins Healthy Future Task Force Treatments Subcommittee Roundtable
- Apr 20, 2022
A Troubling Policy Proposal
- Apr 18, 2022
Prioritizing Minority Health
- Apr 5, 2022
IGT Statement on the Introduction of the Medicaid VBPs for Patients Act (H.R. 7389)
- Feb 25, 2022
Rare Disease Day Spotlight: Hope for HPP Patients
- Feb 1, 2022
Changing the Way We Look at Huntington’s Disease
- Nov 19, 2021
IGT Statement on CMS Final Rule on Medicaid Value-based Purchasing Arrangements
- Aug 7, 2021
IGT Statement on Senate's FY2022 Appropriations Bill
- Jun 29, 2021
Patient Perspective: Khrystal Davis
- Apr 29, 2021
Howard University’s Dr. Sudha Sharma on the Importance of Addressing Health Inequities
- Apr 27, 2021
IGT Statement on ICER’s Analysis of the Accelerated Approval Pathway
- Apr 19, 2021
The Importance of National Minority Health Month
- Mar 25, 2021
NEW IGT Policy Resources Available
- Mar 2, 2021
IGT Recognizes Rare Disease Day
- Dec 23, 2020
IGT Comments on CMS Final Rule on Value-based Purchasing Arrangements
- Dec 22, 2020
Patient Perspective: Erin Frey with CureDuchenne
- Sep 23, 2020
Patient Perspective: Cure SMA
- Sep 8, 2020
Dr. Peter Marks Clarifies FDA’s Approach to Gene Therapies After CRL for Hemophilia A Treatment
- Aug 25, 2020
Patient Perspective: EveryLife Foundation for Rare Diseases
- Jul 21, 2020
IGT Comments on CMS Proposed Rule on Value-based Purchasing Arrangements
- Jul 16, 2020
IGT Webinar on CMS Proposed Rule on Value-based Purchasing
- Jul 7, 2020
IGT to Host Webinar on CMS Proposed Rule on Value-based Purchasing
- Jun 19, 2020
IGT Statement on CMS Proposed Rule to Facilitate Value-based Purchasing Arrangements
- May 11, 2020
Patient Perspective: Susan Ruediger
- May 1, 2020
IGT Joins Axios to Host Webinar on Medical Research During a Crisis
- Apr 28, 2020
FDA’s Dr. Peter Marks on Ways to Preserve Ongoing Medical Research During the Pandemic
- Apr 7, 2020
Patient Perspective: Seth Rotberg
- Feb 19, 2020
NEW INSTITUTE LAUNCHED TO ENSURE THE U.S. HEALTHCARE SYSTEM IS READY FOR GENE THERAPIES
- Feb 16, 2020
Manufacturing: the next breakthrough in gene therapy
- Feb 16, 2020
FDA News Release: FDA Continues Strong Support of Innovation in Development of Gene Therapy Products
- Feb 11, 2020
Progress in Gene Therapy Needs to Be Accelerated